Bibliography
- ECNP. Eur. Neuropsychophannacology (2003):13\(Suppl. 4)
- FASSBENDER K, MASTERS C, BEYREUTHER K: Alzheimer's disease: molecular concepts and therapeutic targets. Naturwissenschaften (2001) 88(6):261–267.
- SELKOE DJ, SCHENK D: Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Ann. Rev Pharmacol. Toxicol. (2003) 43:545–84.
- ••This article reviews the current state ofknowledge in AD with a particular emphasis on the arnyloid-I3 pathway and how it relates to new drug development for AD.
- LAHIRI DK, FARLOW MR, SAMBAMURTI K, GREIG NH, GIACOBINI E, SCHNEIDER LS: A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curt Drug Targets (2003) 4(2):97–112
- ••This article presents a comprehensiveoverview of the current status of all major pathways involved in neurodegeneration and in the pathogenesis of AD. It details the rationale behind novel drug targets currently being investigated in AD therapeutics.
- EDBAUER D, WINKLER E, REGULA JT, PESOLD B, STEINER H, HAASS C: Reconstitution of gamma-secretase activity. Nat. Cell Biol. (2003) 5(5):486–488.
- WINBLAD B, JELIC V: Treating the full spectrum of dementia with memantine. mt. Geriatr. Psychiatry(2003) 18\(Suppl. 1):S41–46.
- HOCK C, KONIETZKO U, STREFFERJ et al.: Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 38(4):547–554.
- ••This paper discusses immunisation therapy for AD and reports a somewhat positive result with the amyloid-I3 vaccine in human AD patients.
- WINBLAD B, BLUM KI: Hints of a therapeutic vaccine for Alzheimer's? Neuron (2003) 38(4):517–518.
- LAHIRI DK: 6th International Conference on Alzheimer's disease and Parkinson's disease. Expert Opin. Investig. Drugs (2003) 12(8):1433–1440.